- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.54 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x NAD: NICOTINAMIDE-ADENINE-DINUCLEOTIDE(Non-covalent)
- 4 x NUC: (2E)-3-[(7S)-7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl]-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide(Non-covalent)
NUC.2: 15 residues within 4Å:- Chain A: G.97, F.98, A.99, L.104, Y.150, P.158, N.159, Y.160, L.199, A.200, S.202, I.204, F.207, M.210
- Ligands: NAD.1
12 PLIP interactions:12 interactions with chain A- Hydrophobic interactions: A:L.104, A:Y.150, A:N.159, A:A.200, A:I.204, A:I.204, A:F.207
- Hydrogen bonds: A:A.99, A:A.99
- Water bridges: A:G.101
- pi-Stacking: A:Y.160, A:Y.160
NUC.4: 16 residues within 4Å:- Chain B: G.97, F.98, A.99, G.101, L.104, Y.150, P.158, N.159, Y.160, L.199, A.200, S.202, I.204, F.207, M.210
- Ligands: NAD.3
13 PLIP interactions:13 interactions with chain B- Hydrophobic interactions: B:L.104, B:N.159, B:A.200, B:I.204, B:F.207
- Hydrogen bonds: B:A.99, B:A.99, B:G.101, B:Y.160
- Water bridges: B:L.199, B:S.202
- pi-Stacking: B:Y.160, B:Y.160
NUC.6: 15 residues within 4Å:- Chain C: G.97, F.98, A.99, L.104, Y.150, P.158, N.159, Y.160, L.199, A.200, S.202, I.204, F.207, M.210
- Ligands: NAD.5
13 PLIP interactions:13 interactions with chain C- Hydrophobic interactions: C:L.104, C:Y.150, C:N.159, C:A.200, C:I.204, C:I.204, C:F.207
- Hydrogen bonds: C:A.99, C:A.99, C:Y.160
- Water bridges: C:G.101
- pi-Stacking: C:Y.160, C:Y.160
NUC.8: 16 residues within 4Å:- Chain D: G.97, F.98, A.99, G.101, L.104, Y.150, P.158, N.159, Y.160, L.199, A.200, S.202, I.204, F.207, M.210
- Ligands: NAD.7
12 PLIP interactions:12 interactions with chain D- Hydrophobic interactions: D:L.104, D:N.159, D:A.200, D:I.204, D:F.207
- Hydrogen bonds: D:A.99, D:A.99, D:G.101
- Water bridges: D:L.199, D:S.202
- pi-Stacking: D:Y.160, D:Y.160
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Parker, E.N. et al., An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections. Acs Cent.Sci. (2022)
- Release Date
- 2022-12-14
- Peptides
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
AD
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.54 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x NAD: NICOTINAMIDE-ADENINE-DINUCLEOTIDE(Non-covalent)
- 4 x NUC: (2E)-3-[(7S)-7-amino-8-oxo-6,7,8,9-tetrahydro-5H-pyrido[2,3-b]azepin-3-yl]-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Parker, E.N. et al., An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections. Acs Cent.Sci. (2022)
- Release Date
- 2022-12-14
- Peptides
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
AD
B